iBio hires endocrinologist Molly Carr as CMO

iBio, Inc. appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer effective July 31, 2026, to lead global clinical strategy, medical affairs and regulatory initiatives for its obesity and cardiometabolic pipeline.

Rhea-AI Filing Summary

iBio, Inc. appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer effective July 31, 2026, to lead global clinical strategy, medical affairs and regulatory initiatives for its obesity and cardiometabolic pipeline. She brings more than 30 years of clinical, academic and biopharmaceutical experience, including senior roles at Eli Lilly and GlaxoSmithKline.

Under an employment agreement, Dr. Carr will receive an annual base salary of $470,000 and an annual target cash bonus equal to 40% of salary. As a material inducement to join, she was granted a non-qualified stock option to purchase 430,000 shares at $1.40 per share, with 25% vesting after one year and the remainder in 36 monthly installments. If terminated without Cause or resigning for Good Reason, she may receive salary continuation, pro rata or target bonus, COBRA coverage, and, following a Sale Event, accelerated vesting of time-based equity awards, subject to conditions.

8-K Event Classification

3 items: 5.02, 8.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Base Salary: $470,000 per year Target Bonus: 40% of base salary Inducement Option Size: 430,000 shares +4 more

7 metrics

Base Salary $470,000 per year Annual base salary for Molly Carr under her employment agreement

Target Bonus 40% of base salary Annual target cash bonus opportunity for the CMO role

Inducement Option Size 430,000 shares Non-qualified stock option granted as a material inducement to employment

Exercise Price $1.40 per share Exercise price of the inducement stock option granted on July 31, 2026

Option Term 10 years Length of the non-qualified stock option granted to Dr. Carr

Standard Severance Salary Continuation 9 months Base salary continuation if terminated without Cause or for Good Reason

Change-in-Control Severance Salary Continuation 12 months Base salary continuation after certain terminations around a Sale Event

Key Terms

Inducement Award, Nasdaq Listing Rule 5635(c)(4), non-qualified stock option, Sale Event, +2 more

6 terms

Inducement Award financial

"approved a non-qualified stock option award to purchase 430,000 shares of the Company’s common stock (the “Inducement Award”)"

An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.

Nasdaq Listing Rule 5635(c)(4) regulatory

"The Inducement Award was approved in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock option financial

"approved a non-qualified stock option award to purchase 430,000 shares of the Company’s common stock"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Sale Event financial

"during the period beginning one month prior to, or ending twelve months following, a Sale Event (as defined in the Plan)"

COBRA premium coverage financial

"Company-paid COBRA premium coverage for nine months"

change in control financial

"accelerated vesting in connection with a change in control of the company or certain involuntary terminations"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did iBio (IBIO) disclose in this 8-K?

iBio appointed Molly Carr, M.D. as Chief Medical Officer effective July 31, 2026. She will lead global clinical strategy, medical affairs and regulatory initiatives for iBio’s obesity and cardiometabolic pipeline, drawing on over 30 years of endocrinology and metabolic disease experience.

What are the main compensation terms for iBio (IBIO) CMO Molly Carr?

Dr. Carr’s employment agreement provides a $470,000 base salary and an annual target cash bonus equal to 40% of salary. She also participates in standard executive benefit plans available at iBio, subject to performance criteria set by the Compensation Committee.

What inducement equity award did iBio (IBIO) grant to Molly Carr?

iBio granted Dr. Carr a non-qualified stock option for 430,000 shares as an inducement award under Nasdaq Listing Rule 5635(c)(4), with an exercise price of $1.40 per share, a ten-year term, and time-based vesting over four years.

How does Molly Carr’s stock option from iBio (IBIO) vest?

The inducement option vests 25% on the one-year anniversary of Dr. Carr’s employment start date. The remaining 75% vests in 36 substantially equal monthly installments, conditioned on her continued service through each applicable vesting date.

What severance protections does iBio (IBIO) provide its new CMO?

If terminated without Cause or she resigns for Good Reason, Dr. Carr is eligible for nine months of salary continuation, pro rata annual bonus and nine months of COBRA premiums. Following a Sale Event, benefits increase to 12 months salary, target bonus, COBRA and full vesting of time-based equity.

How does Molly Carr’s appointment support iBio (IBIO)’s strategy?

Dr. Carr will guide iBio’s clinical programs, including candidates IBIO-600 and IBIO-610, toward later-stage development. Her background in insulin, glucagon and broader cardiometabolic diseases aligns with iBio’s focus on long-acting antibody therapeutics for obesity and related conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 07:06 AM Accepted by SEC EDGAR 08/04/2026 - 07:05 AM Learn about SEC filing dates

0001420720false00014207202026-07-222026-07-22

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 31, 2026

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​	​
001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

​

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

​

​

​

​

Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. (the “Company”).

Dr. Molly Carr, M.D., age 59, is a physician executive with extensive experience in the biotechnology and pharmaceutical industries. Immediately prior to joining the Company, she served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly and Company (“Eli Lilly”) since 2021. In that role, she oversaw clinical development activities for Eli Lilly’s insulin and glucagon portfolio, including late-stage development programs for efsitora, a once-weekly insulin candidate, as well as other diabetes and metabolic disease therapies. Prior to assuming that position, Dr. Carr served as Senior Medical Fellow, Associate Vice President, Diabetes Business Development and External Innovation at Eli Lilly from 2018 to 2021, where she led the evaluation of external business development opportunities and supported licensing and strategic transactions in diabetes and related metabolic diseases. Before joining Eli Lilly, Dr. Carr held positions of increasing responsibility at GlaxoSmithKline plc, including Endocrine Scientific Lead, Metabolic Pathways & Cardiovascular R&D Unit, and Global Medical Affairs Lead for albiglutide. Earlier in her career, she served in clinical development and medical leadership roles at CSL Behring and Wyeth LLC and held academic appointments in endocrinology and metabolism at Northwestern University, the University of Washington, and the University of Pennsylvania. Dr. Carr received a B.A. in Biology from Barnard College and an M.D. from Columbia College of Physicians and Surgeons. She is board certified in Endocrinology, Diabetes and Metabolism and Internal Medicine.

Pursuant to the terms of an employment agreement that the Company entered into with Dr. Carr, dated July 31, 2026 (the “Employment Agreement”), Dr. Carr will receive an annual base salary of $470,000 and will be eligible to earn an annual target cash bonus equal to 40% of her base salary, based on individual and Company performance criteria established by the Compensation Committee of the Board of Directors. Dr. Carr will also be entitled to participate in the Company’s employee benefit plans and programs generally available to similarly situated executives.

As an inducement material to Dr. Carr’s entering into employment with the Company, the Compensation Committee of the Board of Directors approved a non-qualified stock option award to purchase 430,000 shares of the Company’s common stock (the “Inducement Award”). The Inducement Award was granted outside of the Company’s 2023 Omnibus Incentive Plan (the “Plan”), but subject to the terms and conditions of the Company’s standard form of stock option agreement and, except as otherwise required to qualify as an inducement award, substantially the same terms and conditions applicable to awards granted under the Plan. The Inducement Award was granted on July 31, 2026, has an exercise price equal to the closing price of the Company’s common stock on the grant date, a term of ten years, and will vest as follows: twenty-five percent (25%) of the shares subject to the Inducement Award will vest on the one-year anniversary of Dr. Carr’s commencement of employment and the remaining seventy-five percent (75%) will vest in thirty-six (36) substantially equal monthly installments thereafter, subject to Dr. Carr’s continued service through each applicable vesting date. The Compensation Committee determined that the Inducement Award constituted a material inducement to Dr. Carr’s acceptance of employment with the Company. The Inducement Award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

If Dr. Carr’s employment is terminated by the Company without Cause or if she resigns for Good Reason (each as defined in the Employment Agreement), and subject to her execution and non-revocation of a release of claims, she will be entitled to receive severance benefits consisting of (i) continued payment of her base salary for nine months, (ii) a pro rata share of any annual bonus earned during the year of termination based on actual performance, and (iii) Company-paid COBRA premium coverage for nine months.

In addition, if Dr. Carr’s employment is terminated by the Company without Cause during the period beginning one month prior to, or ending twelve months following, a Sale Event (as defined in the Plan), or if she resigns for Good Reason within twelve months following a Sale Event, then, subject to her execution and non-revocation of a release of claims, she will be entitled to enhanced severance benefits consisting of (i) continued payment of her base salary for twelve months, (ii) a cash payment equal to her target annual bonus for which she would have been eligible during the year of termination, (iii) full vesting acceleration of her outstanding unvested time-based equity awards, and (iv) Company-paid COBRA premium coverage for twelve months.

The Employment Agreement also contains customary provisions regarding confidentiality, assignment of intellectual property, non-solicitation of employees and business relationships for one year following termination of employment, non-disparagement, and other customary restrictive covenants.

The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

There are no family relationships between Dr. Carr and any director or executive officer of the Company, and there are no transactions involving Dr. Carr requiring disclosure under Item 404(a) of Regulation S-K.

​

Item 8.01     Other Events.

On August 4, 2026, the Company publicly announced the appointment of Dr. Carr as its Chief Medical Officer and the grant of the Inducement Award described above. A copy of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company is furnishing this Current Report, in part, to satisfy the public disclosure requirements of Nasdaq Listing Rule 5635(c)(4) with respect to the Inducement Award.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the federal securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

​

Item 9.01.     Financial Statements and Exhibits.

(d)    Exhibits.

​	​	​
Exhibit No.	​ ​ ​	Description
10.1†	​	Employment Agreement, dated July 31, 2026, by and between iBio, Inc. and Molly Carr, MD
​	​	​
99.1	​	Inducement Press Release, dated August 4, 2026
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

† The Company has omitted certain portions of this exhibit which are indicated therein by [***] in order to apply confidential treatment. The Company agrees to furnish unredacted copies of these exhibits to the SEC upon request.

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​	​
	IBIO, INC.
Date: August 4, 2026	By:	/s/ Marc Banjak
		Name:	Marc Banjak
​	​	Title:	Chief Legal Officer

​

​

​

Exhibit 99.1

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company’s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.

Prior to joining iBio, Dr. Carr held senior clinical development, medical affairs, business development and academic positions at leading biopharmaceutical companies and institutions, including Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University and the University of Washington. Most recently, she served as Clinical Head and Associate Vice President of Lilly’s Insulin and Glucagon Franchise, where she oversaw the company’s insulin portfolio and clinical development team, including the Phase 3 program for efsitora, a once-weekly insulin, as well as programs spanning prandial insulin, nasal glucagon, biosimilars and legacy insulins. Dr. Carr earned her M.D. from Columbia University College of Physicians and Surgeons and completed her residency and fellowship in endocrinology at the University of Washington.

“Adding Molly to our leadership team is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic,” said Martin Brenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “Her rare combination of deep scientific expertise in endocrinology and metabolic disease, together with hands-on experience leading clinical programs across all stages of development, will be invaluable as we advance IBIO-600 and IBIO-610 into their next clinical phases. Her appointment reflects iBio’s growth into a clinical-stage company and strengthens our ability to execute on our programs with the rigor and focus required to bring them closer to patients.”

“The science behind iBio’s clinical candidates is closely aligned with my experience in endocrinology, obesity, muscle biology and cardiometabolic disease, and I believe these programs have the potential to meaningfully improve body composition and overall quality of life for patients,” added Dr. Carr. “I was also drawn to iBio’s clear clinical vision, highly collaborative culture, and commitment to translating differentiated science into new medicines. I look forward to working with this world-class research team to advance these candidates through the clinic.”

iBio also today announced the company has granted Dr. Carr options to purchase 430,000 shares of its common stock as inducement awards outside the company’s 2023 Omnibus Incentive Plan. The grant was

​

approved by the Compensation Committee and was made as an inducement material to the employee entering into employment in accordance with Nasdaq Lising Rule 5635(c)(4).

The option award has an exercise price of $1.40 per share, the closing price of the company’s common stock on July 31, 2026, the grant date, and has a ten-year term. The option will vest 25% on the one-year anniversary of the date of grant and after one year following the grant date, 6.25% of the options granted will vest for each additional 3 months of employment provided Dr. Carr remains employed by the company through the applicable vesting dates. These inducement awards also provide for accelerated vesting in connection with a change in control of the company or certain involuntary terminations of Dr. Carr’s employment.

About iBio, Inc.

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

For more information, visit www.ibioinc.com or follow us on LinkedIn.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Dr. Carr leading the company’s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development; the company advancing its obesity and cardiometabolic pipeline into the clinic; Dr. Carr’s expertise and hands-on experience leading clinical programs across all stages of development being invaluable to the company as it advances IBIO-600 and IBIO-610 into their next clinical phases; Dr. Carr’s appointment reflecting iBio’s growth into a clinical-stage company and strengthening the company’s ability to execute on its programs with the rigor and focus required to bring them closer to patients; Dr. Carr’s belief that these programs have the potential to meaningfully improve body composition and overall quality of life for patients; iBio’s commitment to translating differentiated science into new medicines; the vesting of the option granted to Dr. Carr; and the accelerated vesting of the inducement award in the event of termination in connection with a change in control of the company or certain involuntary terminations of Dr. Carr’s employment. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the contributions to be made by Dr. Carr; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Corporate Contact:
iBio, Inc.
​

Investor Relations
ir@ibioinc.com

Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EX-99.1 12.0 KB

Agreements & Contracts

• EX-10.1 EX-10.1 94.4 KB

Other Documents

• EX-101 EX-101.SCH 3.4 KB
• EX-101 EX-101.DEF 2.8 KB
• EX-101 EX-101.LAB 14.3 KB
• EX-101 EX-101.PRE 9.3 KB